Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein (a) or Lp (a) levels in adults with high risk of cardiovascular events in a ...

Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...

While having HDL levels above 60 mgdL is often seen as a sign of good health it’s not a standalone indicator Read ahead to ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of ...

American Heart Association Scientific Sessions 2024, Abstract 4171286 - The oral medication muvalaplin may safely lower high ...